![]() International experience in applying framework for Multistakeholder Research Initiatives (coordinator of EU H2020 Responsible Research Innovation MULTI-ACT project) Mario Alberto Battaglia. AISM is working on an international project to standardize and harmonize PROs between their own PROMOPRO-MS database and iConquerMS (Accelerated Cure Project) network. Lead Agency: Italian MS Societyħ AISM Lead Agency Contributing to the Patient Registry Initiative promoted by EMA PROs for MS research and healthcare. MS Societies and Current iPRO Partnership MSIF. Meeting MSIF Strategy MSIF Lead Agency “Global collaborations for registries or databases in relation to Patient Reported Outcomes”Ħ MS SOCIETIES AND CURRENT IPRO PARTNERSHIP MSIF LEAD AGENCY: ITALIAN MS SOCIETY A global and multistakeholders initiative MSIF Lead Agencyĥ MSIF STRATEGY Peer Baneke. MSIF Strategy Multistakeholders PRO Lerici’s meeting Peer Baneke. Introduction of the Members of Panel Peer Baneke, UK Multiple Sclerosis International Federation (CEO) Mario Alberto Battaglia, Italy Italian Multiple Sclerosis Society Foundation (President) Giancarlo Comi, Italy European Charcot Foundation (President) Patrick Vermersch, France European Charcot Foundation (Board Member) Moderator: Pamela Valentine, Canada MS Society of Canada (President & CEO)Ĥ PATIENT REPORTED OUTCOME CALL TO ACTION Overall, patient registries provide the unique patient perspective and has the potential to benefit research, drug development, and patient experiences.3 Members of the panel Peer Baneke, UK Mario Alberto Battaglia, Italy These registries have also been used in patient-focused drug development and to inform efforts during the COVID-19 pandemic. The symptoms patients ranked with the highest importance are not the ones usually studied in clinical research, highlighting the potential work that can be done and information that can be provided with patient registries. Issues with mobility were ranked lower on the list, but they tend to be most frequently studied in standard clinical research. The top-rated symptoms included fatigue, sleep disturbances, wellbeing, and anxiety. In o ne example involving that registry, data were collected on the symptoms having the greatest impact on patients’ lives. This network is all about “people plus data, and how that can move research forward. This network has a variety of functions - all run by patients, including a governance board, research committee, engagement committee, and others. This registry was created in 2014 and has over 7, 000 participants, all either patients or caregivers affected by MS. McBurney followed his presentation with a registry case example, the iConquer MS patient – powered research network. This step is vital to achieving diversity and representativeness in a registry population. To facilitate patient engagement with registries, one must establish trust with communities and involve patients in the development of the registr y and corresponding studies. Registries can collect information on individuals with a particular disease, follow disease progression, document patient experience and preference, and even can be used as surveillance tools to monitor quality of care and safety. ![]() Source: AHRQ Effective Health Care ProgramĬ reat ing a patient registry, starts with defin ing its purpose and identifying the patient community and types of RWD that will be collected. M ay also be referred to as clinical registries, disease registries, and outcomes registries.C ompiled to learn about that disease or condition, monitor outcomes and quality of care, or to develop research or therapeutics.An organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves a predetermined scientific, clinical, or policy purpose(s).The Agency for Healthcare Research and Quality’s (AHRQ) defines patient registr ies as : T here is no single, standardized, agreed – upon definition as the complexity of registries varies greatly – ranging from simple surveys to sophisticated, linked datasets. The term “p atient registr y” is sometimes used interchangeably with clinical registr y, disease registr y, and outcomes registr y. Speakers included Robert McBurney, PhD, Chief Research Officer, Accelerated Cure Project for Multiple Sclerosis and Vanessa Boulanger, MSc, Director of Research Programs, National Organization for Rare Disorders. The National Health Council and the Duke-Margolis Center for Health Policy continued the introductory series on real- world data (RWD) and real-world evidence (RWE) with a webinar introducing patient registries, which are made up of RWD and often inform RWE studies. ![]() By Sara Gray, Associate, Research & Programs
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |